Border to Coast Pensions Partnership Ltd Buys Shares of 386,715 Boston Scientific Corporation $BSX

Border to Coast Pensions Partnership Ltd purchased a new stake in shares of Boston Scientific Corporation (NYSE:BSX) during the first quarter, Holdings Channel.com reports. The fund purchased 386,715 shares of the medical equipment provider’s stock, valued at approximately $24,341,000.

Several other institutional investors and hedge funds also recently made changes to their positions in BSX. FWL Investment Management LLC bought a new stake in Boston Scientific in the 2nd quarter valued at about $26,000. Swiss RE Ltd. bought a new position in Boston Scientific during the fourth quarter worth about $26,000. Garton & Associates Financial Advisors LLC bought a new position in Boston Scientific during the fourth quarter worth about $26,000. Bangor Savings Bank increased its stake in shares of Boston Scientific by 94.7% in the fourth quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 142 shares in the last quarter. Finally, Board of the Pension Protection Fund purchased a new position in shares of Boston Scientific in the fourth quarter worth about $29,000. Institutional investors own 89.07% of the company’s stock.

Analyst Ratings Changes

BSX has been the topic of a number of recent research reports. UBS Group dropped their price target on shares of Boston Scientific from $120.00 to $105.00 and set a “buy” rating on the stock in a research note on Tuesday, March 17th. Raymond James Financial reiterated an “outperform” rating and issued a $88.00 price objective (down from $97.00) on shares of Boston Scientific in a research note on Monday, March 30th. Jefferies Financial Group lowered their target price on shares of Boston Scientific from $100.00 to $67.00 and set a “buy” rating on the stock in a report on Wednesday. Needham & Company LLC restated a “buy” rating and set a $77.00 target price on shares of Boston Scientific in a research report on Monday, May 18th. Finally, Canaccord Genuity Group cut their price target on Boston Scientific from $71.00 to $70.00 and set a “buy” rating for the company in a report on Monday, June 1st. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Boston Scientific has a consensus rating of “Moderate Buy” and an average price target of $83.36.

Boston Scientific Trading Down 0.1%

Shares of Boston Scientific stock opened at $44.16 on Friday. The company’s 50-day moving average price is $52.87 and its 200-day moving average price is $71.13. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. Boston Scientific Corporation has a 12-month low of $43.89 and a 12-month high of $109.50. The company has a market cap of $65.64 billion, a price-to-earnings ratio of 18.48, a PEG ratio of 0.85 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating the consensus estimate of $0.79 by $0.01. The company had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. Boston Scientific’s revenue for the quarter was up 11.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, equities analysts expect that Boston Scientific Corporation will post 3.36 earnings per share for the current fiscal year.

Boston Scientific announced that its Board of Directors has initiated a share buyback plan on Monday, May 18th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s management believes its stock is undervalued.

Insider Activity

In other news, Director Cheryl Pegus purchased 1,770 shares of Boston Scientific stock in a transaction dated Wednesday, May 20th. The stock was purchased at an average cost of $56.49 per share, for a total transaction of $99,987.30. Following the transaction, the director directly owned 1,770 shares of the company’s stock, valued at approximately $99,987.30. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director David C. Habiger purchased 2,250 shares of the firm’s stock in a transaction dated Wednesday, May 20th. The stock was purchased at an average cost of $55.92 per share, for a total transaction of $125,820.00. Following the acquisition, the director owned 13,878 shares of the company’s stock, valued at approximately $776,057.76. This trade represents a 19.35% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought 9,800 shares of company stock worth $554,012 in the last three months. Corporate insiders own 0.34% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.